MedTrace Logo

Sodium Bicarbonate as an Alternative to Potassium Citrate for Kidney Stones

NCT07408076 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-12

No results posted yet for this study

Summary

Kidney stones affect 1 in every 11 people in the US each year. In patients with kidney stones who are prescribed medications for stone management, only 30.2% are adherent to a medication regime and even fewer, only 13.4 % are adherent with citrate medications.

Prescription potassium citrate can be expensive for many patients, leading to non-compliance. Sodium bicarbonate is a potential medication alternative that is cheaper and can potentially alkalinize the urine and/or decrease the risk of future kidney stones. However, efficacy of alternatives to potassium potassium citrate are not well studied.

This study seeks to evaluate sodium bicarbonate and assess its ability to alkalinize urine in a cohort of patients with kidney stones and compare this to prescription potassium citrate.

Conditions

  • Kidney Stones, Urolithiasis, Hypocitraturia
  • Nephrolithiasis

Interventions

DRUG

Potassium Citrate

20 mEq Kcit twice a day (40 mEq daily

DRUG

Sodium Bicarbonate

650 mg sodium bicarbonate twice a day (35.2 mEq daily)

Sponsors & Collaborators

Principal Investigators

  • Kymora B Scotland, MD, PhD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2026-08-01
Completion
2028-02-01
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Iceland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07408076 on ClinicalTrials.gov